Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent

ObjectiveCan biochip arrays identify which individuals with metastatic disease will respond to an anti-metastatic agent?Design and methodsCytokine and cell adhesion arrays (Randox Ltd) were measured over 1 month in 9 research participants receiving CTCE-9908 in a Phase I/II study.ResultsResearch participants with stable disease (n = 2) had significantly higher soluble VCAM-1 as compared to those that progressed.DiscussionVCAM-1 measurement early during CTCE-9908 treatment might be used as a surrogate for response.